OIPE JUL 29 2005 PATENT & TRADEMARK OFFICE

IPW

PATENT
ATTORNEY DOCKET NUMBER: 50125/085001

Certificate of Mailing: Date of Deposit: 7/27/05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne
Printed name of person mailing correspondence

Colleen Coyne
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eggert Stockfleth	Art Unit:	1632
Serial No.:	10/682,612	Examiner:	
Filed:	October 9, 2003	Customer No.:	21559
Title:	THE USE OF POLYPHENOL FOR THE TREATMENT OF ACTINIC KERATOSIS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 27 July 2006

Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

F:\50125\50125.085001 2nd supplemental Information Disclosure Statement.doc

OIPE JC181
JUL 29 2005
PATENT & TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/085001
		Serial No.	10/682,612
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Eggert Stockfleth
		Filing Date	October 9, 2003
		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	07/27/05

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	US 2003/0166583	09/04/03	Yoa-Pu Hu et al.			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/51048	07/19/01	WIPO			
	WO 04/026323	04/01/04	WIPO			
	WO 04/053097	06/24/04	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Cao et al., "Angiogenesis Inhibited By Drinking Tea," *Nature* 398: 381 (1999).
	Linden et al., "Chemoprevention of Non-Melanoma Skin Cancer: Experience with a Polyphenol From Green Tea," *European Journal of Cancer* 38: S24 (2002).
	Linden et al., "Epigallocatechin Gallate in the Chemoprevention of Non-Melanoma Skin Cancer, with Biomarker Studies of Actinic Keratoses, Sun-Damaged, and Non Sun-Damaged Skin: Results of a Clinical Trial," *Frontiers in Cancer Prevention Research* A113: 29 (2003).
	McCarty " Polyphenol-mediated Inhibition of AP-1 Transactivating Activity May Slow Cancer Growth By Impeding Angiogensis and Tumor Invasiveness," *Medical Hypothesis* 50: 511-514 (1998) (XP-000957651).
	Mukhtar et al., "Green Tea Polyphenols Induce Apoptosis and Alter the Progression of Cell Cycle in Human Epidermoid Carcinoma Cells A431," *Proceedings of the American Association for Cancer Research and American Society of Clinical Oncology* 38: 580 (1997) (XP-000997348).
	Proniuk et al., " Preformulation Study of Epigallocatechin Gallate, a Promising Antioxidant for Topical Skin Cancer Prevention," *Journal of Pharmaceutical Sciences* 91: 111-116 (2002) (XP- 002270297).
	Zhu et al., "Study of Tea Polyphenol as a Reversal Agent for Carcinoma Cell Lines' Multidrug Resistance(Study of TP as a MDR Reversal Agent)," *Nuclear Medicine and Biology* 28: 735-740 (2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	